Contact | Print version | PDF version | Send article | RSS feed

Isotechnika Inc. strengthens patent position for ISA247

28 Nov 2007 - Isotechnika Inc. announced that the Company has been issued Norwegian Patent No. 324042 for its lead immunosuppressive drug, ISA247. Obtaining the patent in Norway completes the protection over the novel structural features of ISA247 in Europe. A total of 83 patents worldwide have been issued relating to ISA247's structure, composition, formulation and methods of synthesis.
 
"In accordance with our overall strategic plan, we continue to secure patent protection worldwide in anticipation of acquiring market approval for ISA247," stated Dr. Robert Foster, Isotechnika's Chairman and Chief Executive Officer. "This indicates that ISA247 will have exclusivity for at least another 15 years. Additional claims for ISA247 will be pursued to ensure that intellectual property is secured in all of the major markets worldwide."